Omeros | OMER - Equity Capital And Reserves


Omeros reported $-228.68M in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.





Equity Capital And Reserves Change Date
Adma Biologics USD 390.32M 86.99M Mar/2026
Alnylam Pharmaceuticals USD 1.08B 286.2M Mar/2026
BioMarin Pharmaceutical USD 6.21B 125.11M Mar/2026
Cytokinetics USD -826.57M 166.94M Mar/2026
Gilead Sciences USD 23.52B 897M Mar/2026
Heron Therapeutics USD 9.14M 4.15M Mar/2026
Immunic USD 151.23M 157.91M Mar/2026
Insmed USD 704.85M 34.12M Mar/2026
Knight Therapeutics CAD 767.27M 480K Dec/2025
MacroGenics USD 21.2M 34.39M Mar/2026
Omeros USD -228.68M 15.13M Jun/2025
Pacira USD 653.89M 39.22M Mar/2026
Pfizer USD 90.1B 3.63B Mar/2026
Rockwell Medical USD 30.41M 1.11M Jun/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Sarepta Therapeutics USD 1.51B 364.48M Mar/2026
United Therapeutics USD 5.9B 1.2B Mar/2026
Vertex Pharmaceuticals USD 19.36B 696.1M Mar/2026
Xoma USD 87.94M 15.5M Sep/2025